A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.
about
Pharmacological interventions for non-ulcer dyspepsiaPharmacological interventions for non-ulcer dyspepsiaElectroacupuncture to treat gastroesophageal reflux disease: study protocol for a randomized controlled trialGene polymorphisms associated with functional dyspepsiaIncidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.Influence of the patient-practitioner interaction context on acupuncture outcomes in functional dyspepsia: study protocol for a multicenter randomized controlled trialSerotonin transporter gene polymorphism may be associated with functional dyspepsia in a Japanese population.Serotonin and GI Disorders: An Update on Clinical and Experimental Studies.Drug treatment of functional dyspepsia.Review article: current and emerging therapies for functional dyspepsia.Serotonergic modulation of visceral sensation: upper gastrointestinal tract.Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics.Serotonin receptor 3A polymorphism c.-42C > T is associated with severe dyspepsiaPharmacology of serotonin: what a clinician should know.Pathophysiology as a basis for understanding symptom complexes and therapeutic targets.Functional dyspepsia: motor abnormalities, sensory dysfunction, and therapeutic options.Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study.Review article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders--the clinical evidence.Drugs acting on serotonin receptors for the treatment of functional GI disorders.Gastrointestinal motility disorders: an update.Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity.Effect of acupuncture and its influence on cerebral activity in functional dyspepsia patients: study protocol for a randomized controlled trial.Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders.Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome.Acupuncture for functional dyspepsia: study protocol for a two-center, randomized controlled trial.Review article: endpoints used in functional dyspepsia drug therapy trials.Review article: adherence to Rome criteria in therapeutic trials in functional dyspepsia.Treatment of functional dyspepsia and gastroparesis.ACG and CAG Clinical Guideline: Management of Dyspepsia.Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans.Inter-digestive and post-prandial antro-pyloro-duodenal motor activity in humans: effect of 5-hydroxytryptamine 1 receptor agonism.The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial.Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron.Influence of the 5-HT3 receptor antagonist ondansetron on gastric sensorimotor function and nutrient tolerance in healthy volunteers.Disturbed bowel habits in patients with non-ulcer dyspepsia.
P2860
Q24234257-AFE0C7AB-FFE4-44B2-B3C5-F78F6BD90C0AQ24244245-5031CA40-E088-4CA8-8F64-B93C27E7C86DQ27333906-AE5C9668-A771-48CF-8BD8-FD9EBA9D61F4Q28082606-657A4549-24D2-4C79-99C1-0717966DB550Q31036400-24C71231-1EFF-492C-B50A-882AB63196F8Q33909374-0A738E05-F961-410A-A14C-27E3276603FBQ33945867-1A8DEE94-0BEC-471B-9F72-571EBD020B08Q34317503-9C1B7B55-AAE2-4930-B6C3-5CF2AFBD6BA2Q34529448-2285B11B-7920-4983-BE50-40D105581F35Q34553942-AD816627-8B75-48B1-9EEE-AF7AED1263E9Q34699852-5744B064-0900-4054-B803-1978FBBF7018Q34893529-1C6EE413-AA42-4384-BC53-D0CD7D35A2CBQ35541477-63546C6D-731B-4BF3-AE9E-64AAEDCC2FFFQ35596862-7DDA72A4-06A2-4EDD-8CBE-1F71DA034196Q35746810-9AB70F44-C4C7-4E10-9B90-1405C2D60B9EQ35747997-E8BFC217-E595-41E4-BB2D-2B69D0354FDFQ35893549-D2728E16-06A4-4AD8-BCFD-D13CE4EE7980Q36072575-A578CDAB-4910-4D91-B555-EA5AB2DDAD9CQ36478089-45C1CFC1-00B7-479D-8340-76AC2962283CQ36540251-06373684-EA33-4D5A-A584-07F915DE73F5Q36728938-46DA4270-1CEF-4D4E-8263-D6E7DCA0D8BCQ36759762-E41513E4-F3E2-462E-A578-84088B43BD4BQ36874388-0E6D0CB8-636D-4BBD-810D-1DE1DF881A06Q37608344-122CB723-3EC7-442A-8B9D-8BE2EAFBA16CQ37714702-A0C67665-82C2-4EE8-8C9A-59FB8E9D93A9Q37827564-D78E75B8-3078-4593-ABDD-04648F745F33Q38233254-8153AE82-988C-486E-821E-7AB589A35859Q38244400-208040A3-6ADC-4EC8-8FEC-1DFA1FB0E121Q39385451-E305FC1B-6B31-4E4D-8BCC-BC7931B7996DQ43144574-B546D914-054C-46D0-9A4B-2439100D10A9Q43892498-9ED56474-427E-482B-9423-FA5F0E3E3690Q44813870-5DA13731-373B-41B5-B696-C2E2623F665FQ46887384-9A4FFC7C-B439-46AF-A5BA-604B076F3228Q46921547-33A2DD23-D2A8-4A6A-963C-0BE524F91DA3Q48162056-BD1F5C91-D2AC-4FE7-B108-6E7ED18596A1Q51795709-F5237A9E-9D21-4B64-BA7B-06D4B2612016
P2860
A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
A dose-ranging, placebo-contro ...... nts with functional dyspepsia.
@en
A dose-ranging, placebo-contro ...... nts with functional dyspepsia.
@nl
type
label
A dose-ranging, placebo-contro ...... nts with functional dyspepsia.
@en
A dose-ranging, placebo-contro ...... nts with functional dyspepsia.
@nl
prefLabel
A dose-ranging, placebo-contro ...... nts with functional dyspepsia.
@en
A dose-ranging, placebo-contro ...... nts with functional dyspepsia.
@nl
P2093
P2860
P1476
A dose-ranging, placebo-contro ...... nts with functional dyspepsia.
@en
P2093
Kleoudis C
Van Zanten SV
P2860
P304
P356
10.1046/J.1365-2036.2001.00941.X
P407
P577
2001-04-01T00:00:00Z